Research Article
Plasma Lipidomics Profiling to Identify the Biomarkers of Diagnosis and Radiotherapy Response for Advanced Non-Small-Cell Lung Cancer Patients
Table 6
ROC curve analysis of NSCLC patients and healthy controls.
| Bad/good response pre-RT | NSCLC pre-RT/Con | Elements | AUC | value | Elements | AUC | value |
| PG (18 : 0/20 : 1) | 0.850 | 0.006 | PS (18 : 0/20 : 0) | 0.993 | <0.001 | PG (18 : 0/14 : 0) | 0.825 | 0.004 | Cholesterol | 0.992 | <0.001 | PS (18 : 1/16 : 1) | 0.796 | 0.002 | PI (18 : 0/20 : 4) | 0.969 | <0.001 | PG (18 : 1/18 : 3) | 0.775 | 0.022 | PI (14 : 0/18 : 1) | 0.957 | <0.001 | PG (18 : 0/18 : 2) | 0.767 | 0.009 | MAG 22 : 5 | 0.956 | <0.001 | PS (16 : 0/18 : 2) | 0.750 | 0.045 | MAG 22 : 0 | 0.914 | <0.001 | PS (14 : 0/22 : 4) | 0.746 | 0.015 | PS (20 : 0/16 : 1) | 0.874 | <0.001 | PS (20 : 0/20 : 3) | 0.729 | 0.012 | MAG 22 : 3 | 0.863 | <0.001 | PG (18 : 0/20 : 2) | 0.729 | 0.021 | MAG 20 : 0 | 0.845 | <0.001 | S-1-P | 0.729 | 0.026 | FFA(24 : 0) | 0.839 | <0.001 | PI (14 : 0/22 : 4) | 0.725 | 0.025 | PS (20 : 0/20 : 5) | 0.833 | <0.001 | 27 OH cholesterol | 0.725 | 0.043 | PS (18 : 1/22 : 4) | 0.830 | <0.001 | PA (14 : 0/20 : 4) | 0.721 | 0.023 | PS (18 : 0/18 : 0) | 0.818 | <0.001 | PA (18 : 2/22 : 4) | 0.717 | 0.027 | PG (16 : 0/18 : 1) | 0.810 | <0.001 | PS (16 : 0/20 : 5) | 0.713 | 0.028 | PS (18 : 0/16 : 1) | 0.809 | <0.001 | PA (18 : 0/20 : 5) | 0.713 | 0.046 | PS (18 : 0/20 : 3) | 0.806 | <0.001 | PS (20 : 0/16 : 1) | 0.700 | 0.042 | | | | PI (20 : 0/22 : 5) | 0.692 | 0.045 | | | | PA (14 : 0/20 : 3) | 0.688 | 0.035 | | | |
|
|
NSCLC: non-small-cell lung cancer; pre-RT: preradiotherapy; AUC: area under the curve.
|